Zobrazeno 1 - 10
of 73
pro vyhledávání: '"S, Rubinraut"'
Publikováno v:
Journal of Controlled Release. 142:214-220
Here we describe the design and application of OSu-FMS-MAL-S-(CH(2))(15)-COOH, an agent that associates with albumin while linked to a peptide or a protein with sufficient affinity (Ka=2 to 2.6 x 10(5)M(-1)) to protract the action of short- lived pep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c07383572fe8f5209bbfb1c3f2e91f0
https://doi.org/10.1016/j.jconrel.2009.10.028
https://doi.org/10.1016/j.jconrel.2009.10.028
Autor:
Mati Fridkin, Yoram Shechter, Haim Tsubery, Keren Sasson, Marina Mironchik, S. Rubinraut, Yonit Marcus
Publikováno v:
European Journal of Pharmaceutics and Biopharmaceutics. 70:19-28
We attempted to engineer a novel long-acting insulin based on the following properties: (i) action as a prodrug to preclude supraphysiological concentrations shortly after injection; (ii) maintenance of low-circulating level of biologically active in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::262c240bff96854037edbd9dfdd544e0
https://doi.org/10.1016/j.ejpb.2008.03.018
https://doi.org/10.1016/j.ejpb.2008.03.018
Autor:
Illana Gozes, A. Reshef, Ariane Davidson, R. Glazer, Matityahu Fridkin, Terry W. Moody, Rachel Zamostiano, Amos Bardea, A. Ticher, S. Rubinraut, Osnat Ashur-Fabian, G. Lilling, Douglas E. Brenneman, I. E. Ashkenazi
Publikováno v:
Annals of the New York Academy of Sciences. 805:159-169
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11ea196558f5d9268f9d2664f2d52b21
https://doi.org/10.1111/j.1749-6632.1996.tb17481.x
https://doi.org/10.1111/j.1749-6632.1996.tb17481.x
Autor:
Eytan Gershonov, Aviva Kapitkovsky, Haim Tsubery, Yoram Shechter, A. Saul, Mati Fridkin, B. Mester, S. Rubinraut, Keren Sasson, Y. Vachutinski, L. Precido-Patt, Gil Fridkin, Marina Mironchik
Publikováno v:
International Journal of Peptide Research and Therapeutics. 13:105-117
Most peptide and protein drugs are short-lived species in vivo with a circulatory half-life of several minutes. This is particularly valid for non-glycosylated proteins with a molecular mass of less than 50 kDa. Since peptide/protein drugs are not ab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7417373a4906e0ac0259e74ec8335b3b
https://doi.org/10.1007/s10989-006-9052-1
https://doi.org/10.1007/s10989-006-9052-1
Autor:
S. Rubinraut, Orly Perl, Mati Fridkin, Illana Gozes, Eliezer Giladi, Ariane Davidson, Osnat Ashur-Fabian
Publikováno v:
Proceedings of the National Academy of Sciences. 96:4143-4148
The understanding of the molecular mechanisms leading to peptide action entails the identification of a core active site. The major 28-aa neuropeptide, vasoactive intestinal peptide (VIP), provides neuroprotection. A lipophilic derivative with a stea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b40ac8bef7f48a5145ed8531512dc85b
https://doi.org/10.1073/pnas.96.7.4143
https://doi.org/10.1073/pnas.96.7.4143
Autor:
Mati Fridkin, Illana Gozes, Amos Bardea, Michal Bachar, S. Rubinraut, Ariane Davidson, Eli Giladi
Publikováno v:
Journal of Neurobiology. 33:329-342
Stearyl-Nle-17-VIP (SNV) is a novel agonist of vasoactive intestinal peptide (VIP) exhibiting a 100-fold greater potency than the parent molecule and specificity for a receptor associated with neuronal survival. Here, mice deficient in apolipoprotein
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abfba850f5dfad971112d47adc59a59b
https://doi.org/10.1002/(sici)1097-4695(199709)33:3<329::aid-neu10>3.0.co
https://doi.org/10.1002/(sici)1097-4695(199709)33:3<329::aid-neu10>3.0.co
Autor:
Rachel Zamostiano, Douglas E. Brenneman, O. Pearl, Ariane Davidson, A. Reshef, M. Bechar, S. Rubinraut, Eliezer Giladi, Amos Bardea, Mati Fridkin, Illana Gozes
Publikováno v:
Annals of the New York Academy of Sciences. 814:161-166
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc2919045d107087e4e33c10fc6012f1
https://doi.org/10.1111/j.1749-6632.1997.tb46154.x
https://doi.org/10.1111/j.1749-6632.1997.tb46154.x
Publikováno v:
Advances in Experimental Medicine and Biology ISBN: 9780387736563
Introduction Serum amyloid A (SAA) is an acute phase protein associated with pathological amyloid deposits. The present study was aimed toward identification of the minimal amyloid-forming fragment of human SAA1 [1]. This information may lead to a be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8795ef2b9c7f418d52af492772dd08e
https://doi.org/10.1007/978-0-387-73657-0_30
https://doi.org/10.1007/978-0-387-73657-0_30
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 285(2)
Activity-dependent neurotrophic factor (ADNF) is a glia-derived protein that is neuroprotective at femtomolar concentrations. A 14-amino acid peptide of ADNF (ADNF-14) has been reported that protects cultured neurons from multiple neurotoxins. Struct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::436c3b7399644710d8611d97e6d4580a
https://pubmed.ncbi.nlm.nih.gov/9580606
https://pubmed.ncbi.nlm.nih.gov/9580606
Publikováno v:
Neurochemical research. 23(5)
Stearyl-Nle-VIP (SNV) is a novel agonist of vasoactive intestinal peptide (VIP) exhibiting a 100-fold greater potency than the parent molecule and specificity for a receptor associated with neuronal survival. Here, the developmental and protective ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f8219d25ac524114e631248064641af3
https://pubmed.ncbi.nlm.nih.gov/9566607
https://pubmed.ncbi.nlm.nih.gov/9566607